Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
- (-) Prescription medicines (16)
- (-) Weight loss products (1)
- Alert/Advisory (1067)
- Medicine safety (493)
- Medical devices safety (343)
- Safety (61)
- Regulatory compliance (23)
- Import and export (18)
- Listed medicines (16)
- Over the counter (OTC) medicines (14)
- Therapeutic goods regulation (14)
- Complementary medicines (12)
- Australian Register of Therapeutic Goods (ARTG) (11)
- Shortages (11)
- Blood safety (8)
- Non-prescription medicines (7)
- Advertising (4)
- Labelling and packaging (3)
- Sunscreens (3)
- Breast implant hub (2)
- Legislation (2)
- Assessed listed medicines (1)
- Compliance and enforcement hub (1)
- Metal-on-metal hip replacement implants hub (1)
- Registered complementary medicines (1)
Search
16 result(s) found, displaying 1 to 16
-
Safety alertsFurther examples of counterfeit Ozempic-labelled products have been detected and stopped at the Australian border.
-
Market actionsTakeda Pharmaceuticals Australia has issued a product alert for Vyvanse capsules due to minor packaging errors. The medication is safe to use as prescribed.
-
Safety alertsMagnum XXL capsules pose a serious risk to your health and should not be taken.
-
Safety alertsMore prominent warnings are being added to the Product Information and Consumer Medicine Information for all oral and injectable (systemic) fluoroquinolones to strengthen existing warnings about serious side effects.
-
Safety alertsExtra safety information is being added to all montelukast products to highlight the existing warnings about serious behaviour and mood-related changes
-
Medicine shortage alertsPharmacists can use a Serious Scarcity Substitution Instrument (SSSI) to dispense Protaphane Penfill human insulin in the place of a Protaphane InnoLet cartridge.
-
Medicine shortage alertsPharmacists may dispense alternative brands or strengths without a new prescription.
-
Safety alertsRobust Extreme capsules pose a serious risk to your health and should not be taken.
-
Medicine shortage alertsPharmacists can now substitute one Orencia 125 mg product for the other
-
Market actionsThere have been reports of the dose counter stopping after the 10th dose and not locking after the 60th dose. If this happens, you should return the product to your place of purchase or contact Boehringer Ingelheim.
-
Safety alertsThere are new warnings about the risks of heart attack and stroke with taking romosozumab (Evenity). The Product Information (PI) and Consumer Medicine Information (CMI) have been updated to reflect these risks.
-
Safety alertsOur safety advisory includes information for consumers and health professionals about low levels of nitrosamine impurity in medicines containing sitagliptin.
-
Safety alertsFind out how we are investigating low levels of the nitrosamine impurity in medicines containing fluoxetine. Read information for consumers and health professionals.
-
-
Safety alertsTGA investigation - potential low levels of contamination with N-nitrosovarenicline
-